IKZF1 and acute lymphoblastic leukemia: Either the initial study from Mullighan C (22) in which 258 ALL pediatric patients were enrolled or the following numerous large scale clinical researches (67, 86–90) which included more than 1000 pediatric patients and the relatively small-scale adult clinical researches (91, 92), all showed that IKZF1 deletion was a strong prognostic factor and confer an increased risk of relapse and poor outcome with inferior EFS as well as OS in BCP-ALL.